A new era of treatment for chronic lymphocytic leukaemia?
Mené sur 29 patients atteints d'une leucémie lymphocytaire chronique et deux patients atteints d'un lymphome à petits lymphocytes (âge médian : 71 ans), cet essai de phase Ib/II évalue la toxicité et l'activité de l'ibrutinib en traitement de première ligne
Chronic lymphocytic leukaemia is the most common adult leukaemia, and a progressive incurable disease. Although recent advances with chemoimmunotherapy have improved survival for patients without significant medical comorbidities, these regimens cause striking myelosuppression and immunosuppression. These adverse effects can be especially severe in individuals older than 65—70 years—who are most at risk of development of chronic lymphocytic leukaemia—and the toxicities of the chemoimmunotherapy ...
The Lancet Oncology , commentaire, 2012